Preliminary Approval Granted for $32 Million GoodRx and Criteo Settlement
Key Facts
On September 8, 2026, the U.S. District Court for the Northern District of California granted preliminary approval to a proposed $32 million settlement between GoodRx and ad-tech company Criteo in a lawsuit accusing the companies of disclosing users’ health and personal information. Approval remains provisional pending a final approval hearing scheduled for February 11, 2027, according to court documents and the settlement notice. The information cited in the allegations includes prescription drug and health condition data, as well as email addresses and phone numbers. GoodRx and Criteo deny the allegations, and preliminary approval is not a final ruling that a violation occurred or an admission of liability. The proposed agreement is a civil settlement of the dispute between the two parties, while other legal claims in the case remain pending.
According to the settlement’s official website, GoodRx and Criteo agreed to pay $32 million into the settlement fund. After expenses approved by the court are deducted, the net fund will be distributed equally among claimants whose claims are accepted. The proposed class definition covers individuals in the United States who used a website, app or service provided by GoodRx before April 20, 2024, subject to specified exclusions. This definition sets a time and geographic scope for the claim, but does not change the fact that the settlement still requires final approval. The deadline to submit a claim, request exclusion or object is December 29, 2026.
The lawsuit alleges that GoodRx disclosed user data through tracking technologies embedded in its platform, and that the data included information on medications and health conditions as well as personal contact details. Case documents refer to technologies associated with Criteo, Meta and Google, but the current agreement covers only GoodRx and Criteo. The settlement documents say Meta and Google are defendants in the same lawsuit but are not included in the agreement, and claims against them are continuing separately. Preliminary approval therefore does not end the entire dispute related to the allegations or resolve the position of the other companies named in it. The lawsuit describes the disclosure as unlawful, while the allegations remain disputed.
The case stems from broader allegations over the sharing of data related to the use of digital prescription services for advertising purposes. The Federal Trade Commission said more than 55 million consumers had visited GoodRx’s website or used its apps since January 2017. In its complaint, the commission said GoodRx in August 2019 compiled lists of users who had purchased particular medications, then uploaded their email addresses, phone numbers and mobile advertising identifiers to Facebook. The commission said the data was used to target users with health-related ads on Facebook and Instagram. The current lawsuit includes allegations that health and personal data were disclosed to advertisers and analytics companies during a period extending, according to the allegations, from 2017 to at least 2020.
In a separate proceeding in 2023, the Federal Trade Commission said it had for the first time applied the Health Breach Notification Rule in an action against GoodRx. The regulatory settlement included a $1.5 million civil penalty and a ban on sharing users’ health data with third parties for advertising purposes. GoodRx said at the time that it disagreed with the commission’s allegations and did not admit to wrongdoing, and that it chose to settle to avoid the time and expense of protracted litigation. That proceeding differs from the current class action in the agency that brought it, the parties involved and the scope of the proposed settlement. The company said in its statement at the time: "We disagree with the Federal Trade Commission’s allegations and do not admit to any wrongdoing. Entering into the settlement allows us to avoid the time and expense associated with protracted litigation."
GoodRx’s annual revenue reached $796.9 million in 2025, up 1% from $792.3 million in 2024, according to its annual results. But prescription transaction revenue fell 6% to $544 million, compared with $577.5 million a year earlier. The company attributed the decline mainly to a decrease in monthly active consumers and shifts in the pharmacy market, including store closures. Net income, meanwhile, rose to $30.4 million in 2025 from $16.4 million in 2024. GoodRx shares, listed under the ticker GDRX, closed at $3.62 on October 22, 2026, according to EL7 data.
The upcoming milestones include the December 29, 2026 deadline to submit a claim, request exclusion or object, followed by the final approval hearing on February 11, 2027. The court will consider the agreement at that hearing before the settlement can become final. Claims against Meta and Google will continue outside this settlement, according to case documents. This means the parties covered by the proposed agreement do not represent all defendants in the lawsuit. The court’s final approval remains the next scheduled step in the GoodRx and Criteo settlement process.